Asthma - Versorgungsleitlinien.de

NVL Asthma, 2. Auflage
Langfassung
Juli 2011, Version 1.3
341. Dachverband der dt.spr. osteologischen Fachgesellschaften (DVO). DVO-Leitlinie 2009 zur
Prophylaxe, Diagnostik und Therapie der Osteoporose. 2009 [cited: 2009 Okt 13]. Available
from: http://www.dv-osteologie.org/dvo_leitlinien/dvo-leitlinie-2009
342. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg
M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma
exacerbations and emergency medical visits in patients with severe persistent asthma.
Allergy 2005;60(3):302-8.
343. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K,
Blogg M, Holgate S. Predicting and evaluating response to omalizumab in patients with
severe allergic asthma. Respir Med 2007;101(7):1483-92.
344. Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses
über eine Änderung der Arzneimittel-Richtlinie in Anlage 4: Therapiehinweis zu Omalizumab
vom 20. Dezember 2007. Dtsch Arztebl 2008;105(20):A-1084-6.
345. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of
Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint
Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol
2007;120(6):1373-7.
346. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of
anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol
2007;120(6):1378-81.
347. Cooper PJ, Ayre G, Martin C, Rizzo JA, Ponte EV, Cruz AA. Geohelminth infections: a review of
the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy
2008;63(4):409-17.
348. Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, Fox H, Cooper PJ. Safety of anti-immunoglobulin
E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp
Allergy 2007;37(2):197-207.
349. Brenner M, Berkowitz R, Marshall N, Strunk RC. Need for theophylline in severe steroidrequiring
asthmatics. Clin Allergy 1988;18(2):143-50.
350. Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in
steroid-dependent asthma. N Engl J Med 1981;304(2):71-5.
351. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane
Database Syst Rev 2004;(3):CD003269.
352. Szefler SJ, Nelson HS. Alternative agents for anti-inflammatory treatment of asthma. J Allergy
Clin Immunol 1998;102(4 Pt 2):S23-S35.
353. van der Wouden JC, Uijen JH, Bernsen RM, Tasche MJ, de Jongste JC, Ducharme F. Inhaled
sodium cromoglycate for asthma in children. Cochrane Database Syst Rev
2008;(4):CD002173.
354. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be
maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J
Allergy Clin Immunol 2006;117(3):563-70.
Gilt nur für
Erwachsene
Gilt nur für
Kinder/Jugendliche
Allgemeine
Empfehlungen
© 2009 225